Background. Single-nucleotide polymorphisms (SNPs) near the IL28B gene have recently been associated with spontaneous hepatitis C virus (HCV) clearance and response to interferon-based therapies in patients with chronic hepatitis C. Because human immunodeficiency virus (HIV) coinfection appears to accelerate HCV-related liver fibrosis progression, any influence of IL28B SNP on the risk of developing cirrhosis might be more easily recognized in the coinfected population.
Background. Single-nucleotide polymorphisms (SNPs) near the IL28B gene have recently been associated with spontaneous hepatitis C virus (HCV) clearance and response to interferon-based therapies in patients with chronic hepatitis C. Because human immunodeficiency virus (HIV) coinfection appears to accelerate HCV-related liver fibrosis progression, any influence of IL28B SNP on the risk of developing cirrhosis might be more easily recognized in the coinfected population.
Methods. All HIV-HCV-coinfected patients who underwent hepatic elastography before initiating a course of pegylated interferon plus ribavirin therapy at 2 Spanish clinics were retrospectively identified. Liver cirrhosis was defined as .14.5 kPa by transient elastography. The IL28B rs12979860 SNP was examined in a blinded fashion.
Results. A total of 304 HIV-HCV-coinfected individuals were analyzed (mean age, 43 years; 80% were male; and 85% were receiving antiretroviral therapy), of whom 18% had cirrhosis. IL28B genotype distribution was as follows: CC, 46%; CT, 43%; and TT, 11%. Cirrhosis was more frequent in CC than CT/TT carriers (24% vs 13%; P 5 .01). Logistic regression analysis revealed that older age (odds ratio [OR], 1.05; 95% confidence interval [CI] , 0.99-1.12]; P 5 .08), past alcohol abuse (OR, 1.97; 95% CI, 0.95-4.06; P 5 .07), and CC IL28B genotype (OR, 2.32; 95% CI, 1.22-4.41; P 5 .01) were predictors of cirrhosis. Interestingly, mean (SD) alanine aminotransferase (ALT) levels were greater (90 6 53 vs 71 6 33 IU/L;, P 5 .01) in IL28B CC than CT/TT carriers during the prior 4.8 6 3.8 years.
Conclusions. The IL28B rs12979860 CC genotype is associated with a higher prevalence of cirrhosis in HIV-HCV-coinfected patients than CT/TT genotypes, suggesting that IL28B CC carriers may experience a more rapid progression of HCV-related liver fibrosis, perhaps as result of increased liver inflammation. Thus, access to HCV treatment is of utmost importance in IL28B CC carriers, in whom treatment response is better and in whom progression to cirrhosis might occur more rapidly.
Chronic hepatitis C virus (HCV) infection is currently the main cause of liver-related morbidity and mortality in developed countries [1] . Given that human immunodeficiency virus (HIV) shares transmission routes with HCV, coinfection is common, being reported in up to one-quarter of HIV-infected individuals worldwide [2] . More importantly, HIV may accelerate the course of HCV-related liver disease, leading to a higher incidence of cirrhosis in this population [3, 4] . This increased risk of cirrhosis correlates with higher rates of hepatocellular carcinoma and liver-related mortality in HIV-HCV-coinfected individuals [5, 6] . Interestingly, uncontrolled HIV replication and low CD4 counts are both associated with accelerated liver fibrosis progression in this population [7] , suggesting that earlier use of antiretroviral therapy could ameliorate this harmful effect [8] . Other factors independently associated with more rapid liver fibrosis progression in chronic HCV infection include: male gender, older age, longer duration of HCV infection and alcohol abuse [9] , while the contribution of high serum HCV-RNA levels, HCV genotype, insulin resistance or antiretroviral drug modality on liver fibrosis progression is less clear [10] [11] [12] .
At the end of 2009, several groups independently found a strong association between single nucleotide polymorphisms (SNPs) near the IL28B gene and response to interferon (IFN) therapy in chronically infected HCV patients [13] [14] [15] , as well as an association with spontaneous HCV clearance following acute infection [16] . These results have been confirmed by others [17] and recently extended to HIV-HCV-coinfected patients [18] . Given that the IL28B gene codes for IFN lambda-3 (IFN-k3), and given that persistent immune mediated liver inflammation enhances hepatic fibrogenesis [19] , we hypothesized that liver fibrosis progression in HIV-infected patients with chronic hepatitis C might be influenced by IL28B genotypes. The ability to measure liver fibrosis using new noninvasive methods in the HIV-HCVcoinfected population, in which hepatic fibrosis is accelerated, provided us a unique opportunity to explore this question.
PATIENTS AND METHODS

Study Population
This is an observational retrospective study of 2 cohorts of HIV-HCV-coinfected patients recruited in Madrid [18] and Andalusia [20] , Spain, that were recently merged in a single database. All subjects completed a full course of pegylated IFN plus ribavirin therapy and had validated outcomes. All underwent liver fibrosis staging at baseline using elastography. Moreover, all had been tested for the IL28B SNP rs12979860 genotypes. Other relevant demographic and laboratory parameters were registered from the medical records. The main exclusion criteria were baseline CD4 cell counts ,300 cells/lL, hepatitis B virus coinfection, current alcohol abuse (ie, consumption of .60 g per day), prior exposure to IFN-based therapy, and prior episodes of hepatic decompensation.
Because we lacked knowledge of the exact date of hepatitis C seroconversion, the duration of HCV infection was estimated indirectly. As in prior studies, it was presumed that infection had occurred during the first year of injection drug use or the year of the first transfusion of blood or blood products. Past alcohol abuse was defined as consumption of .60 g per day for .1 year, according to clinical records. Insulin resistance was determined using the homeostasis model assessment (HOMA), as defined elsewhere {[fasting insulin (IU/L) 3 fasting glucose (mg/dL)]/405} [21] .
Plasma and peripheral blood mononuclear cells (PBMCs) were available for all patients. All patients provided written informed consent for genetic testing. The study protocol was approved by the hospitals' ethics committees.
HCV Load and Genotyping
Plasma HCV-RNA levels were measured using a real-time polymerase chain reaction (PCR) assay (COBAS TaqMan; Roche), which has a lower limit of detection of 10 IU/mL. HCV genotyping was performed using a commercial real time (RT) -PCR hybridization assay (Versant HCV Genotype v2.0 LiPA; Siemens), which maximally reduces the chances of HCV genotype misclassification [22] . Plasma HIV-RNA level was measured using the Versant HIV-1 RNA v3.0 (Siemens), which has a lower limit of detection of 50 copies/mL.
Liver Fibrosis Staging
The extent of liver fibrosis was measured during the 6 months prior to initiation of HCV therapy in all patients using transient elastography by FibroScan (Echosens). Details about this noninvasive method, the examination procedure, and correlation of liver fibrosis estimates with liver biopsy data have been reported elsewhere [23, 24] . The median value of all tests per patient is expressed in Kilopascal (kPa) units. According to previous studies conducted in HIV-HCV-coinfected patients [25] [26] [27] , cutoff values fitting the best with liver fibrosis by METAVIR scores were as follows: ,7.2 kPa for null or minimal liver fibrosis (METAVIR F0-F1), 7.2-9.5 kPa for moderate liver fibrosis (METAVIR F2), 9.6-14.5 kPa for advanced liver fibrosis (METAVIR F3), and .14.5 kPa for cirrhosis (METAVIR F4). The validity of transient elastography for the diagnosis of liver cirrhosis in our merged cohort was further tested in a subset of patients with a paired liver biopsy performed within 3 months of the elastography assessment. Staging of liver inflammation (A) and fibrosis (F) in patients with liver biopsy was done according to METAVIR score.
Genotyping for rs12979860 SNP DNA specimens collected from PBMC for each individual were genotyped using the 5# nuclease assay with allele-specific TaqMan probes (ABI TaqMan allelic discrimination kit) and the ABI7900HT Sequence Detection System (Applied Biosystems) [28] . Genotyping was blinded, and calls were manually inspected and verified before release. The results were reported as 3 categories: CC, CT, or TT. Because prior studies have uniformly shown that IL28B allelic threats behave as an autosomal recessive inheritance [13] [14] [15] [16] [17] [18] , CT and TT were considered together for further analyses.
Statistical Analyses
The main characteristics of the study population and the different parameters evaluated are expressed as means 6 standard deviations or as proportions. Comparisons of continuous variables were performed using parametric or nonparametric tests, as required. The Bonferroni correction was applied for multiple paired comparisons in analysis of variance tests. Associations between different qualitative parameters were explored using the v 2 test or the Fisher exact test, as appropriate. Logistic regression analysis with backward selection was performed to identify variables associated with liver fibrosis staging, and all those with P values ,.5 in the univariate analysis were included in the model. The effect of the IL28B genotypes on liver fibrosis staging adjusted by length of HCV infection was analyzed by Cox regression analysis. The internal validity of transient elastography for the diagnosis of liver fibrosis staging was tested by receiver operating characteristic (ROC) curves, with paired liver biopsy as the gold standard. All statistical analyses were performed using the SPSS software, version 15.0 (SPSS). All P values were 2-tailed and were considered as significant only when ,.05.
RESULTS
Study Population
A total of 304 HIV-HCV-coinfected patients were analyzed. Information regarding liver fibrosis staging and IL28B genotyping was available for all subjects. The main characteristics of the study population are depicted in Table 1 . Mean age was 42 years. Eight percent of patients were male, 86% were former injection drug users, and 19% admitted prior alcohol abuse. Most patients (85%) were under antiretroviral therapy, and 79% had plasma HIV -RNA levels ,50 copies/mL. The current mean CD4 cell count was 552 cells/lL, with 30% of patients having nadir CD4 cell counts ,200 cells/lL. Plasma HIV -RNA levels in subjects who were not receiving antiretroviral therapy were low (mean level, 3.06 log 10 copies/mL). The baseline HOMA index was R4 points in 32% of patients.
HCV-Related Liver Disease
Overall, 72% of patients had ALT levels greater than the upper limit of normal, with a mean value of 87 IU/L. The mean serum HCV RNA level was 6.12 log 10 IU/mL, with 68% of patients having levels .600,000 IU/mL. The distribution of HCV genotypes was as follows: HCV-1, 56%; HCV-3, 32%; and HCV-4, 12%. There were no patients carrying HCV-2. Finally, on the basis of elastography findings, 18% of patients met criteria for cirrhosis (METAVIR F4), 48% had advanced liver fibrosis or cirrhosis (METAVIR RF3), and 30% had null or minimal liver fibrosis (METAVIR F0-F1).
IL28B rs12979860 Genetic Variants
The overall distribution of IL28B alleles was as follows: CC, 46%; CT, 43%; and TT, 11%, which was in Hardy-Weinberg equilibrium (P 5 .81). Mean age, sex, risk transmission category, (Table 2) . With respect to laboratory parameters, the proportion of subjects with undetectable plasma HIV RNA levels, mean viral load in antiretroviral-naive subjects, and mean serum HCV RNA levels were all comparable across all 3 IL28B allelic groups. Compared with patients with genotype CT/TT, those with genotype CC tended to display greater mean HOMA indexes (4.26 vs 3.42; P 5 .27), lower mean CD4 cell counts (518 vs 581 cells/lL; P 5 .04), and greater mean ALT levels (93 vs 82 IU/L; P 5 .14) at baseline. A composite of all prior determinations of CD4 cell counts and ALT levels (mean follow
The proportion of subjects infected with HCV genotypes 1 or 4 was lower among IL28B CC carriers (56%), compared with CT (76%) or TT (88%) carriers (P 5 .001). Finally, mean liver stiffness values were significantly greater in CC carriers than in CT or TT carriers (13.1 vs 9.4 and 9.9 kPa, respectively; P , .05), with a greater proportion of patients with cirrhosis occurring in CC (24%) versus CT (12%) or TT (18%) carriers (P 5 .03).
Predictors of Liver Cirrhosis
The main characteristics of patients with elastographic estimates of cirrhosis versus noncirrhosis are displayed in Table 1 . In a subset of 145 patients with paired results of elastography and liver biopsy, the area under the curve for ROC curves was 0.97 (95% confidence interval [CI], 0.92-1.02) for the diagnosis of cirrhosis, with positive and negative predictive values of 100% and 94%, respectively, confirming a good internal validity of the elastography performed at our centers.
Cirrhotic patients were older (mean age, 43 vs 41 years-old; P 5 .04), had a longer duration of HCV infection (25 vs 23 years; P 5 .03), and more frequently had a history of alcohol abuse (28% vs 17%, P 5 .06) than non-cirrhotics. Cirrhosis was more common in patients with the IL28B genotype CC than CT/ TT (24% vs 13%; P 5 .01). The significant association between IL28B genotypes (CC vs CT/TT) and liver cirrhosis persisted even when the study population was stratified by HCV genotype. Accordingly, liver cirrhosis was more common among CC versus CT/TT genotype carriers infected with either HCV genotype 1 (28% vs 15%; P 5 .04) or HCV genotype 3 (22% vs 6%; P 5 .04) (Figure 1) . The number of patients infected with HCV genotype 4 was too low to permit an adequate comparison. Finally, for the 145 patients with liver biopsy at the time of elastography assessment, histological evidence of cirrhosis was present in 20 CC carriers (31%) and 14 CT/TT carriers (17%; P 5 .06).
On the basis of the results of the univariate analysis (Table 1) , a logistic regression model was built using backward step-wise approach, to explore the relative contribution of the IL28B CC genotype on liver cirrhosis. After adjustments for age, sex, alcohol abuse, HOMA index, ALT level, nadir CD4 cell count, and antiretroviral exposure, older age (odds ratio [OR], 1.05; 95% CI, 0.99-1.12; P 5 .08) and prior alcohol abuse (OR, 1.97; 95% CI, 0.95-4.06; P 5 .07) were found to display a positive association trend with liver cirrhosis, but only the IL28B CC variant was significantly associated with liver cirrhosis (OR, 2.32; 95% CI, 1.22-4.41; P 5 .01) ( Table 3) .
A survival analysis using Cox regression model, in which adjustments for former alcohol abuse, nadir CD4 cell count, ALT level, and exposure to antiretroviral therapy were made, demonstrated that HIV-HCV-coinfected patients carrying the IL28B CC genotype had liver cirrhosis more frequently and within a shorter duration of HCV infection than did CT/TT carriers (hazard ratio, 3.02; 95% CI, 1.24-7.39; P 5 .015) (Figure 2 ).
DISCUSSION
This study suggests an association between the IL28B rs12979860 CC genotype and an increased risk of HCV-related liver cirrhosis in HIV-infected patients. Addressing this population provided us a unique opportunity to examine patients in whom the natural history of HCV-related liver disease is accelerated [5] [6] [7] . It is noteworthy that significant differences between CC and CT/TT IL28B carriers were only seen when comparing cirrhotic patients with the rest of the patients, but not when assessing milder liver fibrosis stages. In this regard, it must be acknowledged that the concordance between elastography and intermediate hepatic fibrosis stages is lower than for cirrhosis [24] [25] [26] . Notwithstanding, the area under the ROC curves in our study using elastography for estimates of META-VIR of at least F3 (0.96; 95% CI, 0.92-0.99) or of F1 or lower (0.95; 95% CI, 0.90-0.98]) were high and comparable to those with liver cirrhosis (data not shown).
Liver fibrosis in patients with chronic hepatitis C is believed to result from immune-mediated phenomena rather than be the direct consequence of a cytopathic effect of HCV replication [29] . An enhanced intrahepatic mRNA expression of proinflammatory cytokines (ie, IFN-c, regulated upon activation normal T-cell expressed and secreted, macrophage inflammatory protein-1a, and interferon-inducible protein-10) has been found in HIV-HCV-coinfected individuals in comparison with HCV-monoinfected patients [30] . Interestingly, the subset of patients with the IL28B CC genotype seems to display greater liver inflammation than individuals harboring CT/TT variants [31] , which in the long run might accelerate liver damage and fibrogenesis [32] . In our study, patients with the IL28B CC genotype had greater mean ALT levels over time than did CT/TT carriers; this might indirectly reflect an enhanced persistent immune response against HCV-infected hepatocytes in the former. In support of this, a retrospective review of recruited patients with liver biopsy specimens showed an average of intense (A3) versus moderate (A2) inflammatory activity by METAVIR in IL28B CC versus CT/TT carriers (data not shown).
The immune pathogenesis of the enhanced liver inflammation and faster fibrosis progression in IL28B CC carriers is still far from clear [33, 34] . Recent data have suggested that IL28B CC carriers might display lower intrahepatic expression of IFN-stimulated genes than patients with CT/TT variants [35] , which is in agreement with prior findings claiming that patients with lower levels of activation of the IFN-signaling cascade might respond better to IFN-based therapy [36] . Thus, attenuated innate immune responses in the livers of IL28B CC carriers might facilitate the antiviral activity of IFN-based therapy. If so, other immune pathways, such as T-cell-mediated adaptive immunity, might account for the increased liver inflammation seen in these patients. In this respect, the IFN-k family seems to upregulate the production of IFN-c in response to viral infections [37] ; given the immunomodulatory effects of IFN-c and its role in recruiting T cells to infected tissues in chronic viral infections [38] , IFN-k could indirectly promote liver inflammation without inducing the expression of IFN-stimulated genes.
As expected, older age and longer duration of HCV infection were also significantly associated with an increased risk of liver cirrhosis in our study population. Although alcohol abuse also tended to be more common among cirrhotic persons, the association did not reach statistical significance, most likely because active, heavy drinkers were originally excluded from the study because only patients to be treated for chronic hepatitis C were considered. Other variables that have been associated with more advanced liver fibrosis in other studies did not emerge as such in our analysis, most likely as a result of possible selection bias. This is the case for low CD4 cell counts, given that only subjects with CD4 cell counts .300 cells/lL were included in the study. Likewise, the impact of uncontrolled high levels of HIV replication on liver fibrosis [7, 8] could not be assessed either. Up to 85% of our patients were receiving antiretroviral therapy, and 79% had undetectable plasma HIV RNA levels. Finally, other parameters, such as insulin resistance, as assessed using the HOMA index, did not demonstrate any significant association with cirrhosis in our population. It must be noted, however, that patients with HOMA scores R4 tended to have METAVIR RF3 estimates more frequently than did the rest of the population (OR, 2.47; 95% CI, 0.82-8.67; P 5 .08), which is in agreement with recent findings from others [39] . HCV-3 genotype has been involved in faster progression of hepatic fibrosis, possibly because of a greater risk for liver steatosis [10] . Although the viral genotype was not associated with the extent of liver fibrosis in our study, the fact that IL28B CC genotype was more prevalent in HCV-3 genotype carriers might reflect a synergistic association, increasing the rate of liver cirrhosis in a somewhat 2-hit pathogenic model. Some limitations of our study must be acknowledged. The retrospective design introduces the risk of unrecognized confounders-for example duration of HCV infection, which was only estimated but not precisely documented. Liver fibrosis was determined using elastography instead of liver biopsy, which may still be considered the gold-standard technique. However, in a subset of patients with paired liver biopsy specimens, we demonstrated the reliability of liver elastography for the diagnosis of cirrhosis. Moreover, in the smaller cohort of patients with METAVIR F4, as determined by liver biopsy, a trend suggesting a positive association between the CC genotype and cirrhosis was also found. Although elastography has demonstrated a good correlation with liver biopsy for the diagnosis of liver cirrhosis, the interobserver variability of this technique is low [40] , and an overestimation of liver stiffness may occur in subjects with more pronounced liver inflammation, such as persons with more-elevated liver enzyme levels [41] . If our hypothesis is correct and IL28B CC carriers display greater hepatic inflammation than do CT/TT carriers, as further supported by elevated ALT levels, then overestimation of liver fibrosis might have occurred in our population. We attempted to correct this effect by including ALT levels at the time of elastography in the logistic regression and Cox survival analyses. Moreover, mean ALT values in cirrhotic and noncirrhotic patients were comparable at the time of elastography examination (82 6 50 vs 89 6 61 IU/L; P 5 .46). Although the role of use of protease inhibitors or nonnucleoside analogues on the progression of liver damage is controversial [42] , the possible effect of specific antiretrovirals could not be assessed because we lacked information on prior antiretroviral history in our database. Finally, choosing a population of patients planned to be treated with pegylated IFN plus ribavirin may have introduced a selection bias (eg, little alcohol abuse, high CD4 cell counts, controlled HIV replication, and good treatment adherence);accordingly, our findings may not apply to the entire HIV-HCV-coinfected population.
In summary, HIV-HCV-coinfected patients carrying the IL28B rs12979860 CC genotype are at greater risk for developing liver cirrhosis than are CT/TT carriers. This worse outcome in the natural history of chronic hepatitis C paradoxically occurs along with increased chances of both spontaneous HCV clearance after acute infection and response to IFN-based therapy in CC versus CT/TT carriers. Enhanced immune-mediated damage in the liver of chronically HCV-infected persons who harbor the CC genotype could hypothetically explain these findings.
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